Actinium Pharmaceuticals

$8.07
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.02 (-0.25%) Today
-$0.06 (-0.74%) As of 11:00 PM UTC after-hours

Why Robinhood?

You can buy or sell ATNM and other stocks, options, and ETFs commission-free!

About ATNM

Actinium Pharmaceuticals, Inc, also called Actinium Pharmaceuticals, is a clinical-stage biopharmaceutical company. It is focused on developing Antibody Radiation-Conjugates, which combine the targeting ability of antibodies with the cell killing ability of radiation. The firm provides its service through Iomab-B, which is studied in the ongoing pivotal Phase 3 Study of Iomab-B in Elderly Relapsed or Refractory Acute Myeloid Leukemia (SIERRA) trial for BMT conditioning. The company was founded in 2002 and is headquartered in New York, NY. The listed name for ATNM is Actinium Pharmaceuticals, Inc.

CEO
Sandesh Seth
Employees
25
Headquarters
New York, New York
Founded
2000
Market Cap
117.81M
Price-Earnings Ratio
—
Dividend Yield
—
Average Volume
476.84K
High Today
$8.27
Low Today
$8.00
Open Price
$8.25
Volume
244.03K
52 Week High
$19.47
52 Week Low
$4.71

ATNM Earnings

-$0.04
-$0.03
-$0.01
$0.00
Q2 FY19
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Estimated
— per share
Actual
Expected May 7, After Hours

You May Also Like

OTRAU
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC. Full disclosure